Skip to content
Find a Provider
Patrick M. Reagan, M.D.

Patrick M. Reagan, M.D.

Cancer

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Appointment (585) 275-5823
Fax (585) 273-5761

Locations

Wilmot Cancer Center

90 Crittenden Boulevard
Rochester, NY 14642

(585) 275-5830 Get Directions

About Me

I am a clinician and researcher specializing in the care of patients with both Non Hodgkin and Hodgkin lymphomas. Areas of particular interest include aggressive B-cell lymphomas, autologous stem cell transplantation and cellular therapy including chimeric antigen receptor (CAR) T-cells.

Lym...
I am a clinician and researcher specializing in the care of patients with both Non Hodgkin and Hodgkin lymphomas. Areas of particular interest include aggressive B-cell lymphomas, autologous stem cell transplantation and cellular therapy including chimeric antigen receptor (CAR) T-cells.

Lymphomas are a complex group of diseases and require a multidisciplinary team to manage. We are fortunate to have an excellent team at the Wilmot Cancer Institute including hematology and oncology, radiation oncology, hematopathology, dermatology, neurology, nursing, advanced practice providers, social work and members of the clinical trials office.

I am actively engaged in clinical trials research and feel that this is an important component of care for lymphoma patients.

Professional Background

Dr. Reagan is an Associate Professor of Medicine at the Wilmot Cancer Institute.

Dr. Reagan received his medical degree from Upstate Medical University in Syracuse, NY. He completed his internship and residency at the University of Virginia. He then served as a chief resident at the Univers...
Dr. Reagan is an Associate Professor of Medicine at the Wilmot Cancer Institute.

Dr. Reagan received his medical degree from Upstate Medical University in Syracuse, NY. He completed his internship and residency at the University of Virginia. He then served as a chief resident at the University of Virginia. He completed his fellowship in hematology at the Wilmot Cancer Institute at the University of Rochester Medical Center.

He started his faculty appointment at the Wilmot Cancer Institute in July 2015.

Faculty Appointments

Associate Professor - Department of Medicine, Hematology/Oncology (SMD)

Credentials

Residency & Fellowship

Fellowship, Hematology & Oncology, University of Rochester Medical Center. 2013 - 2015

Residency, Internal Medicine, University of Virginia-Radiology GME. 2012 - 2013

Residency, Internal Medicine, University of Virginia-Radiology GME. 2010 - 2012

Internship, Internal Medicine, University of Virginia-Radiology GME. 2009 - 2010

Education

MD | SUNY Upstate College of Health Professions. 2009

Awards

Wilmot Cancer Institute Inspiration Award Immune Effector Cell Therapy Team. 2022

Lymphoma Research Foundation Clinical Research Mentoring Program. 2018

American Society of Hematology Clinical Research Training Institute. 2015

John and Carol Bennett Travel Fellowship Award. 2014

Alpha Omega Alpha, Upstate Medical University. 2009

Phi Beta Kappa, St. Lawrence University. 2005

Academic All American, Football, St. Lawrence University. 2004

Beta Beta Beta, Biological Honor Society, St. Lawrence University.

Research

Clinical Trials

A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma

Lead Researcher: Patrick M Reagan

This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabta...

A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma

Lead Researcher: Patrick M Reagan

The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Lead Researcher: Patrick M Reagan

The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in particip...

A Phase 1/2, Open Label, Multicenter Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory CD20+ B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Lead Researcher: Patrick M Reagan

Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLL

Phase 2 Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

Lead Researcher: Patrick M Reagan

The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.

Publications

Journal Articles

Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: Results from the US lymphoma CAR-T consortium.

Jain MD, Jacobs MT, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning MA, Lekakis LJ, Reagan PM, Oluwole OO, McGuirk JP, Deol A, Sehgal A, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL, Ghobadi A

Blood advances.. 2023 November 16 Epub 11/16/2023.

Phase 1 Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment.

Roschewski M, Patel MR, Reagan PM, Saba NS, Collins GP, Arkenau HT, de Vos S, Nuttall B, Acar M, Burke K, White RD, Udriste M, Sharma S, Dougherty B, Stetson D, Jenkins D, Mortlock A, Forcina A, Munugalavadla V, Flinn I

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2023 June 26 Epub 06/26/2023.

Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.

Wallace DS, Rowland C, Hill BT, Baran AM, Casulo C, Reagan PM, Winter A, Karmali R, Winter JN, Gordon LI, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Ma S, Barr PM

Leukemia & lymphoma.. 2023 June 21 :1-4. Epub 06/21/2023.

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.

Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, Rapoport AP, Sureda A, Jacobson CA, Farooq U, van Meerten T, Ulrickson M, Elsawy M, Leslie LA, Chaganti S, Dickinson M, Dorritie K, Reagan PM, McGuirk J, Song KW, Riedell PA, Minnema MC, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani SA, Schupp M, To C, Locke FL,

The New England journal of medicine.. 2023 June 5 Epub 06/05/2023.

Healthcare Utilization Disparities of Adolescent and Young Adults Compared to the Older Lymphoma Population.

Thapa K, Strawderman M, Reagan PM, Barr PM, Zent CS, Friedberg JW, Faugh T, Casulo C

Clinical lymphoma, myeloma & leukemia.. 2023 May 23 Epub 05/23/2023.

Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab for Initial Therapy of Chronic Lymphocytic Leukemia.

Wallace DS, Zent CS, Baran AM, Reagan PM, Casulo C, Rice G, Friedberg JW, Barr PM

Blood advances.. 2023 January 23 Epub 01/23/2023.

PD-1 CAR-T cells provide superior protection against solid tumors.

Sailer CJ, Hong Y, Dahal A, Ryan AT, Mir S, Gerber SA, Reagan PM, Kim M

Frontiers in immunology.. 2023 14 :1187850. Epub 06/14/2023.

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.

Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei MG, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF

Haematologica.. 2022 July 14 Epub 07/14/2022.

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.

Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta N, Dubowy R, D'Andrea A, Wang L, Ogasawara K, Thorpe J, Gordon LI

The Lancet. Oncology.. 2022 July 12 Epub 07/12/2022.

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.

Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2022 June 4 :JCO2102370. Epub 06/04/2022.

Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.

Jacobs MT, Jain MD, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan PM, Oluwole OO, McGuirk J, Deol A, Sehgal A, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Ghobadi A, Locke FL

Clinical lymphoma, myeloma & leukemia.. 2022 May 23 Epub 05/23/2022.

Cytopenia after CAR-T Cell Therapy-A Brief Review of a Complex Problem.

Sharma N, Reagan PM, Liesveld JL

Cancers.. 2022 March 1514 (6)Epub 03/15/2022.

Improving eligibility criteria for first-line trials for patients with DLBCL using a U.S.-based Delphi-method survey.

Harkins RA, Patel S, Lee MJ, Switchenko JM, Ansell SM, Bartlett NL, Blum K, Cashen AF, Casulo C, Friedberg JW, Johnston P, Kahl BS, Leonard JP, Link BK, Lossos IS, Martin P, Maurer MJ, Mehta-Shah N, Reagan P, Westin JR, Koff JL, Flowers CR

Blood advances.. 2022 January 31 Epub 01/31/2022.

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR,

The New England journal of medicine.. 2021 December 11 Epub 12/11/2021.

Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission.

Shadman M, Pasquini MC, Ahn KW, Chen Y, Turtle CJ, Hematti P, Cohen JB, Khimani F, Ganguly S, Merryman RW, Yared JA, Locke FL, Ahmed N, Munshi P, Beitinjaneh A, Reagan P, Herrera AF, Sauter CS, Kharfan-Dabaja MA, Hamadani M

Blood.. 2021 September 27 Epub 09/27/2021.

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) versus salvage chemotherapy in refractory large B-cell lymphoma.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan P, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Crump M, Kuruvilla J, Van Den Neste EW, Farooq U, Navale L, DePuy V, Kim JJ, Gisselbrecht C

Blood advances.. 2021 September 3 Epub 09/03/2021.

Longitudinal Changes in Cognitive Function in a Nationwide Cohort Study of Patients with Lymphoma Treated with Chemotherapy.

Janelsins MC, Mohamed M, Peppone LJ, Magnuson A, Belcher EK, Melnik M, Dakhil S, Geer J, Kamen C, Minasian L, Reagan PM, Mohile SG, Morrow GR, Ahles TA, Heckler CE

Journal of the National Cancer Institute.. 2021 July 13 Epub 07/13/2021.

Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells.

Wallace D, Reagan PM

Drugs.. 2021 March 30 Epub 03/30/2021.

Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.

Reagan PM, Friedberg JW

Future oncology.. 2021 January 15 Epub 01/15/2021.

How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies.

Reagan PM, Neelapu SS

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2021 January 12 :JCO2001616. Epub 01/12/2021.

Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel.

Spiegel JY, Dahiya S, Jain MD, Tamaresis JS, Nastoupil L, Jacobs MT, Ghobadi A, Lin Y, Lunning M, Lekakis LJ, Reagan P, Oluwole OO, McGuirk JP, Deol A, Goy A, Vu K, Andreadis C, Munoz J, Bennani NN, Vose J, Dorritie KA, Neelapu SS, Locke FL, Rapoport AP, Hill B, Miklos DB

Blood.. 2020 November 6 Epub 11/06/2020.

Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.

Rodgers TD, Williams AM, Baran A, Reagan PM, Casulo C, Zent CS, Evans A, Friedberg JW, Barr PM

Leukemia & lymphoma.. 2020 October 25 :1-8. Epub 10/25/2020.

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.

Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, Oluwole OO, Reagan PM, Lekakis LJ, Lin Y, Sherman M, Better M, Go WY, Wiezorek JS, Xue A, Bot A

Blood advances.. 2020 October 134 (19):4898-4911. Epub 1900 01 01.

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2020 May 13 :JCO1902104. Epub 05/13/2020.

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM

The New England journal of medicine.. 2020 April 2382 (14):1331-1342. Epub 1900 01 01.

Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma.

Rodgers TD, Baran A, Reagan PM, Casulo C, Zent C, Evans A, Burack R, Williams AM, Friedberg JW, Barr PM

British journal of haematology.. 2019 December 17 Epub 12/17/2019.

Advancing age and the risk of bleomycin pulmonary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin Lymphoma.

Thomas TS, Luo S, Reagan PM, Keller JW, Sanfilippo KM, Carson KR

Journal of geriatric oncology.. 2019 October 24 Epub 10/24/2019.

Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation.

Loh KP, Baran A, Lee CY, Alshaibani A, Rutherford SC, Hu J, Casulo C, Barr PM, Friedberg JW, Reagan PM

Leukemia & lymphoma.. 2019 July 8 :1-4. Epub 07/08/2019.

Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib.

Tomlinson SB, Sandwell S, Chuang ST, Johnson MD, Vates GE, Reagan PM

Leukemia research.. 2019 May 2883 :106164. Epub 05/28/2019.

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS

The Lancet. Oncology.. 2018 November 30 Epub 11/30/2018.

Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience.

Williams AM, Baran AM, Casulo C, Reagan P, Friedberg JW, Helber M, Moore J, Baloga E, Zent CS, Barr PM

Clinical lymphoma, myeloma & leukemia.. 2018 October 13 Epub 10/13/2018.

Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.

Frank MJ, Reagan PM, Bartlett NL, Gordon LI, Friedberg JW, Czerwinski DK, Long SR, Hoppe RT, Janssen RS, Candia AF, Coffman RL, Levy R

Cancer discovery.. 2018 October 8 (10):1258-1269. Epub 08/28/2018.

Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.

David RJ, Baran A, Loh KP, Casulo C, Barr PM, Friedberg JW, Reagan PM

Clinical lymphoma, myeloma & leukemia.. 2018 August 29 Epub 08/29/2018.

Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.

Rodgers TD, Reagan PM

Expert opinion on emerging drugs.. 2018 June 23 (2):111-122. Epub 06/06/2018.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY

The New England journal of medicine.. 2017 December 28377 (26):2531-2544. Epub 12/10/2017.

Current treatment of double hit and double expressor lymphoma.

Reagan PM, Davies A

Hematology. 2017 December 82017 (1):295-297. Epub 1900 01 01.

Reassessment of Anti-CD20 Therapy in Lymphoid Malignancies: Impact, Limitations, and New Directions.

Reagan PM, Friedberg JW

Oncology.. 2017 May 1531 (5):402-11. Epub 1900 01 01.

Chemotherapy-free treatment in non-Hodgkin lymphoma: a steep learning curve.

Reagan PM, Barr PM

The Lancet. Haematology.. 2017 April 4 (4):e152-e153. Epub 03/15/2017.

Poor survival with high-dose chemotherapy and autologous stem cell support in double-hit and double-expressor B-cell lymphomas. Translational Cancer Research, 2017. 6: p. S249-S253.

Reagan, P.M. and J.W. Friedberg.

Translational Cancer Research,. 2017; 6: S249-S253.

Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma.

Reagan PM, Baran A, Kelly JL, Barr PM, Casulo C, Chengazi VU, Friedberg JW

Clinical lymphoma, myeloma & leukemia.. 2016 June 16 (6):322-328.e2. Epub 04/02/2016.

Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma.

Reagan PM, Friedberg JW

Current treatment options in oncology.. 2015 July 16 (7):32. Epub 1900 01 01.

Brentuximab vedotin for the treatment of Hodgkin's and non-Hodgkin's lymphoma.

Reagan, P.M. and J.W. Friedberg.

Expert Opinion on Orphan Drugs. 2015; 3(5): p. 609-618.

Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma.

Reagan PM, Friedberg JW

Future oncology.. 2015 11 (10):1543-53. Epub 1900 01 01.

Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy.

Reagan P, Pani A, Rosner MH

American journal of kidney diseases : the official journal of the National Kidney Foundation.. 2014 January 63 (1):141-7. Epub 09/08/2013.

The snow-shoveler's ST elevation myocardial infarction.

Janardhanan R, Henry Z, Hur DJ, Lin CM, Lopez D, Reagan PM, Rudnick SR, Koshko TJ, Keeley EC

The American journal of cardiology.. 2010 August 15106 (4):596-600. Epub 1900 01 01.

Chemosensory responses to CO2 in multiple brain stem nuclei determined using a voltage-sensitive dye in brain slices from rats.

Erlichman JS, Boyer AC, Reagan P, Putnam RW, Ritucci NA, Leiter JC

Journal of neurophysiology.. 2009 September 102 (3):1577-90. Epub 06/24/2009.